非布司他片、痛风定胶囊联合治疗长期高尿酸血症30例临床观察

【目的】探析非布司他片、痛风定胶囊联合治疗长期高尿酸血症的临床疗效及安全性。【方法】选择本院2011年1月至2015年3月期间门诊病房就诊60例长期高尿酸患者作为研究对象,随机数字表法分为观察组与对照组,各30例。对照组应用非布司他片治疗,观察组在对照组基础上联合痛风定胶囊进行治疗。比较两组疗效；比较治疗1周、12周及24周时的治疗血清高尿酸水平达标率；治疗前、治疗12周、治疗24周时血清尿酸与可溶性细胞间粘附分子-1(sICAM-1)水平；治疗前后谷丙转氨酶(ALT)、谷草转氨酶(AST)及治疗期间不良反应发生率。【结果】观察组治疗1周、12周、24周的血清高尿酸水平达标率分别为93.3%(28/30)、83.3%(25/30)、76.7%(23/30),均高于对照组,差异有统计学意义(P <0.05)。两组治疗前血清尿酸与 sICAM-1水平的差异无统计学意义(P >0.05),治疗后两组血清尿酸与 sICAM-1均降低,且观察组血清尿酸与sICAM-1均低于对照组,差异有统计学意义(P <0.05)。两组治疗后 ALT与 AST未发生明显变化,组间差异无统计学意义(P >0.05),提示两组治疗方案对肝功能影响轻微。观察组不良反应发生率为13.3%(4/30),对照组为9.9%(3/30),差异无统计学意义(χ2=0.115,P =0.734>0.05)。【结论】非布司他片、痛风定胶囊联合治疗长期高尿酸血症具有较佳疗效,患者症状得到明显缓解,血清尿酸与 sICAM-1水平大幅降低,且安全性高,肝功能未受明显影响,值得借鉴推广。

Clinical Observation on Febuxostat Tablets Combined with Tongfengding Capsules in Treatment of Long-Term Hyperuricemia of 3 0 Cases

Obj ective]To explore the clinical curative effect and safety of Febuxostat Tablets combined with Tongfengding Cap-sules in the treatment of long-term hyperuricemia.[Methods]Sixty patients with long-term high uric acid treated in the outpatient wards of our hospital from January 2011 to March 2015 were selected as the study subjects and were divided into the observation group and the control group according to the random number table with 30 cases in each group.The control group were treated with Febux-ostat Tablets .Based on this,the observation group were additionally treated with Tongfengding Capsules.The curative effect was com-pared between the two groups.The control rates of serum high uric acid levels at 1 week,12 weeks and 24 weeks after the treatment, levels of serum uric acid and soluble intercellular adhesion molecule (sICAM-1)before the treatment ,12 weeks and 24 weeks after the treatment,and alanine aminotransferase (ALT),aspartate aminotransferase (AST)before and after the treatment and the incidence rates of adverse reactions during the treatment in the two groups were compared.[Results]1 week,12 weeks and 24 weeks of treat-ment later,the control rates of serum high uric acid levels in the observation group [93.3% (28/30),83.3% (25/30),76.7% (23/30)]were higher than those in the control group,the difference was statistically significant (P<0.05).The differences in levels of se-rum uric acid and sICAM-1 between the two groups before the treatment were not statistically significant (P >0.05).After the treat-ment,serum uric acid and sICAM-1 in the two groups decreased and those in the observation group were lower than those in the con-trol group (P <0.05).After the treatment,there were no significant changes of hepatorenal function indexes such as ALT and AST in the two groups.The differences between groups were not statistically significant (P >0.05),which indicated that the effect of the treatment methods on hepatorenal function in the two groups was slight.The incidence rate of adverse reactions in the observation group was 13.3% (4/30)while in the control group was 9.9% (3/30),the differences had no statistical significance (χ2=0.115,P=0.734>0.05).[Conclusion]Febuxostat Tablets combined with Tongfengding Capsules in the treatment of long-term hyperuricemia is of better curative effects.The symptoms of patients were significantly relieved and levels of serum uric acid and sICAM-1 significantly decreased.With high safety,hepatic function would not be affected obviously .It is worthy of reference and promotion.